Dosing and Administration

SPRAVATO® dosing 
and administration

Actor portrayal.

TRD flexible dosing at a glance1

TRD flexible dosing at a glance1

In Study 2 (long-term), 39% of patients received the 56-mg dose, and 61% received the 84-mg dose of SPRAVATO®

SPRAVATO® does not require daily dosing and should be administered in conjunction with an oral AD

*Evidence of therapeutic benefit should be evaluated at the end of the induction phase to determine need for continued treatment.

Dosing frequency should be individualized to the lowest frequency required to maintain remission/response.

As determined by the prescribing physician.

Treatment-resistant depression administration

SPRAVATO® should be self-administered by the patient under the supervision of a healthcare professional in a certified SPRAVATO® treatment center.1

Treatment-resistant depression administration

Read the full Dosing & Administration Guide before training and supervising patients

Please see “Dosing and Administration” and “Instructions for Use” in the full Prescribing Information.

spravato experience

Learn about the SPRAVATO® experience for adult patients with TRD

Post-administration observation and discharge

eye-icon

Healthcare providers are required to observe patients for at least 2 hours.

 Because of the possibility of delayed or prolonged sedation or dissociation in some cases, patients should be monitored by a healthcare provider for at least 2 hours following each treatment

transportation

Patients will require transportation from the treatment center.

 Caution patients that SPRAVATO® may impair their ability to drive, and not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep

callout-background

Next: Start patients on SPRAVATO®

Learn more

Reference:

1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceutials, Inc. July 2020.